MicroRNA-542 promotes mitochondrial dysfunction and SMAD activity and is elevated in intensive care unit–acquired weakness

American Journal of Respiratory and Critical Care Medicine

Volumn 196, Issue 11, 2017, Pages 1422-1433

  Garros, Roser Farre ^a   Paul, Richard ^a,c   Connolly, Martin ^a   Lewis, Amy ^a   Garfield, Benjamin E ^a   Natanek, S Amanda ^a   Bloch, Susannah ^a,c   Mouly, Vincent ^d   Griffiths, Mark J ^b   Polkey, Michael I ^c   Kemp, Paul R ^a  

^a Div Biomed Sci Sir Alexander F   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

MicroRNA; Mitochondrial function; Skeletal muscle wasting; SMAD signaling

Indexed keywords

MICRORNA; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; DISEASE MODEL; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; MALE; METABOLISM; MITOCHONDRION; MOUSE; MUSCLE WEAKNESS; QUADRICEPS FEMORIS MUSCLE; SIGNAL TRANSDUCTION;

ANIMALS; CRITICAL CARE; DISEASE MODELS, ANIMAL; HUMANS; INTENSIVE CARE UNITS; MALE; MICE; MICRORNAS; MITOCHONDRIA; MUSCLE WEAKNESS; QUADRICEPS MUSCLE; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 85038116826     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201701-0101OC     Document Type: Article

References (37)

1. Man WD, Kemp P, Moxham J, Polkey MI. Skeletal muscle dysfunction in COPD: clinical and laboratory observations. Clin Sci (Lond) 2009;117: 251–264.
2. De Jonghe B, Bastuji-Garin S, Sharshar T, Outin H, Brochard L. Does ICU-acquired paresis lengthen weaning from mechanical ventilation? Intensive Care Med 2004;30:1117–1121.
3. De Jonghe B, Sharshar T, Lefaucheur JP, Authier FJ, Durand-Zaleski I, Boussarsar M, Cerf C, Renaud E, Mesrati F, Carlet J, et al.; Groupe de Réflexion et d’Etude des Neuromyopathies en Réanimation. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 2002;288:2859–2867.
4. Ali NA, O’Brien JM Jr, Hoffmann SP, Phillips G, Garland A, Finley JC, Almoosa K, Hejal R, Wolf KM, Lemeshow S, et al.; Midwest Critical Care Consortium. Acquired weakness, handgrip strength, and mortality in critically ill patients. Am J Respir Crit Care Med 2008;178:261–268.
5. Fletcher SN, Kennedy DD, Ghosh IR, Misra VP, Kiff K, Coakley JH, Hinds CJ. Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med 2003;31: 1012–1016.
6. Swallow EB, Reyes D, Hopkinson NS, Man WD, Porcher R, Cetti EJ, Moore AJ, Moxham J, Polkey MI. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax 2007;62:115–120.
7. Bloch SA, Lee JY, Syburra T, Rosendahl U, Griffiths MJ, Kemp PR, Polkey MI. Increased expression of GDF-15 may mediate ICU-acquired weakness by down-regulating muscle microRNAs. Thorax 2015;70:219–228.
8. Bloch SA, Lee JY, Wort SJ, Polkey MI, Kemp PR, Griffiths MJ. Sustained elevation of circulating growth and differentiation factor-15 and a dynamic imbalance in mediators of muscle homeostasis are associated with the development of acute muscle wasting following cardiac surgery. Crit Care Med 2013;41:982–989.
9. Patel MS, Lee J, Baz M, Wells CE, Bloch S, Lewis A, Donaldson AV, Garfield BE, Hopkinson NS, Natanek A, et al. Growth differentiation factor-15 is associated with muscle mass in chronic obstructive pulmonary disease and promotes muscle wasting in vivo. J Cachexia Sarcopenia Muscle 2016;7:436–448.
10. Puig-Vilanova E, Martínez-Llorens J, Ausin P, Roca J, Gea J, Barreiro E. Quadriceps muscle weakness and atrophy are associated with a differential epigenetic profile in advanced COPD. Clin Sci (Lond) 2015;128:905–921.
11. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, Davies NA, Cooper CE, Singer M. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002;360:219–223.
12. Jiroutková K, Krajčová A, Ziak J, Fric M, Waldauf P, Džupa V, Gojda J, Němcova-Fürstová V, Kovář J, Elkalaf M, et al. Mitochondrial function in skeletal muscle of patients with protracted critical illness and ICU-acquired weakness. Crit Care 2015;19:448.
13. van den Borst B, Slot IG, Hellwig VA, Vosse BA, Kelders MC, Barreiro E, Schols AM, Gosker HR. Loss of quadriceps muscle oxidative phenotype and decreased endurance in patients with mild-to-moderate COPD. J Appl Physiol 1985;2013:1319–1328.
14. Natanek SA, Gosker HR, Slot IG, Marsh GS, Hopkinson NS, Man WD-C, Tal-Singer R, Moxham J, Kemp PR, Schols AMWJ, et al. Heterogeneity of quadriceps muscle phenotype in chronic obstructive pulmonary disease (COPD); implications for stratified medicine? Muscle Nerve 2013;48:488–497.
15. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL, Wang DZ. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006;38:228–233.
16. Zhang X, Zuo X, Yang B, Li Z, Xue Y, Zhou Y, Huang J, Zhao X, Zhou J, Yan Y, et al. MicroRNA directly enhances mitochondrial translation during muscle differentiation. Cell 2014;158:607–619.
17. Lewis A, Riddoch-Contreras J, Natanek SA, Donaldson A, Man WD, Moxham J, Hopkinson NS, Polkey MI, Kemp PR. Downregulation of the serum response factor/miR-1 axis in the quadriceps of patients with COPD. Thorax 2012;67:26–34.
18. Watson E, Sylvius NB, Viana JLL, Greening N, Barratt J, Smith A. Differential microRNA expression in skeletal muscle of human CKD patients and healthy controls [abstract]. Nephrol Dial Transplant 2016;31:i473–i474.
19. Lewis A, Lee JY, Donaldson AV, Natanek SA, Vaidyanathan S, Man WD, Hopkinson NS, Sayer AA, Patel HP, Cooper C, et al. Increased expression of H19/miR-675 is associated with a low fat-free mass index in patients with COPD. J Cachexia Sarcopenia Muscle 2016;7: 330–344.
20. Farre-Garros R, Natanek SA, Bloch S, Polkey MI, Kemp PR. miR-542: a novel regulator of muscle mass and function [abstract]. J Muscle Res Cell Motil 2015;36:593–594.
21. Farre-Garros R, Paul R, Natanek SA, Griffiths M, Polkey MI, Kemp PR. A microRNA axis that regulates muscle mass and mitochondrial function in response to disease [abstract]. J Muscle Res Cell Motil 2017;S08:O05–O253.
22. Paul R, Polkey M, Kemp P, Griffiths M. S116 GDF-15, the miR-542 cluster and miR-422a are associated with muscle wasting in intensive care unit acquired paresis [abstract]. Thorax 2015;70:A66–A67.
23. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, et al.; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532–555.
24. Bergstrom J. Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. Scand J Clin Lab Invest 1975;35: 609–616.
25. Seymour JM, Ward K, Sidhu PS, Puthucheary Z, Steier J, Jolley CJ, Rafferty G, Polkey MI, Moxham J. Ultrasound measurement of rectus femoris cross-sectional area and the relationship with quadriceps strength in COPD. Thorax 2009;64:418–423.
26. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk–database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform 2011;44:839–847.
27. Wang Y, Huang JW, Castella M, Huntsman DG, Taniguchi T. p53 is positively regulated by miR-542-3p. Cancer Res 2014;74: 3218–3227.
28. Yan X, Liu Z, Chen Y. Regulation of TGF-beta signaling by Smad7. Acta Biochim Biophys Sin (Shanghai) 2009;41:263–272.
29. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998;17:3091–3100.
30. Bloch S, Polkey MI, Griffiths M, Kemp P. Molecular mechanisms of intensive care unit-acquired weakness. Eur Respir J 2012;39: 1000–1011.
31. Brealey D, Singer M. Mitochondrial dysfunction in sepsis. Curr Infect Dis Rep 2003;5:365–371.
32. Saada A, Shaag A, Arnon S, Dolfin T, Miller C, Fuchs-Telem D, Lombes A, Elpeleg O. Antenatal mitochondrial disease caused by mitochondrial ribosomal protein (MRPS22) mutation. J Med Genet 2007;44:784–786.
33. Miller C, Saada A, Shaul N, Shabtai N, Ben-Shalom E, Shaag A, Hershkovitz E, Elpeleg O. Defective mitochondrial translation caused by a ribosomal protein (MRPS16) mutation. Ann Neurol 2004;56:734–738.
34. Fredriksson K, Tjäder I, Keller P, Petrovic N, Ahlman B, Schéele C, Wernerman J, Timmons JA, Rooyackers O. Dysregulation of mitochondrial dynamics and the muscle transcriptome in ICU patients suffering from sepsis induced multiple organ failure. PLoS One 2008;3:e3686.
35. Li Y, Li W, Ying Z, Tian H, Zhu X, Li J, Li M. Metastatic heterogeneity of breast cancer cells is associated with expression of a heterogeneous TGFb-activating miR424-503 gene cluster. Cancer Res 2014;74: 6107–6118.
36. Faraonio R, Salerno P, Passaro F, Sedia C, Iaccio A, Bellelli R, Nappi TC, Comegna M, Romano S, Salvatore G, et al. A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts. Cell Death Differ 2012;19:713–721.
37. Lee JY, Lori D, Wells DJ, Kemp PR. FHL1 activates myostatin signalling in skeletal muscle and promotes atrophy. FEBS Open Bio 2015;5: 753–762.